NPL

		Results
10.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(age-related macular degeneration) *[All Sources(- All Sciences -)]*	124
9.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(diabetic retinopathy) *[All Sources(- All Sciences -)]*	406
8.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(retinal vascularization) *[All Sources(- All Sciences -)]*	8
7.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(ocular) *[All Sources(- All Sciences -)]*	224
6.	TITLE-ABSTR-KEY(vegf and diagnostic) and TITLE-ABSTR-KEY(blood) *[All Sources(- All Sciences -)]*	133
5.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(blood diagnostic) *[All Sources(- All Sciences -)]*	0
4.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(blood) *[All Sources(- All Sciences -)]*	5904
3.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(cressey) *[All Sources(- All Sciences -)]*	0
2.	TITLE-ABSTR-KEY(vegf inhibitor) and TITLE-ABSTR-KEY(cancer) *[All Sources(- All Sciences -)]*	17
1.	TITLE-ABSTR-KEY(vegf) and TITLE-ABSTR-KEY(cancer) *[All Sources(- All Sciences -)]*	3447

C:\Program Files\Stnexp\Queries\10533028.str





chain nodes :
7 9 12 14 15 16 17 22 24 25 31
ring nodes :
1 2 3 4 5 6
chain bonds :
7-9 12-14 12-17 14-15 15-16 22-24 24-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 12-14 14-15 15-16 22-24 24-25
exact bonds :
12-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:O,S,N

G2:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 12:CLASS
14:CLASS 15:CLASS 16:Atom 17:CLASS 22:CLASS 24:CLASS 25:Atom 31:CLASS 32:CLASS
Generic attributes :
9:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

Node 9: Limited
C,C3
N,N1
S,S1
O,O0

=>
Uploading C:\Program Files\Stnexp\Queries\10533028.str













chain nodes :
7 9 12 14 15 16 17 22 24 25 31
ring nodes :
1 2 3 4 5 6
chain bonds :
7-9 12-14 12-17 14-15 15-16 22-24 24-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 12-14 14-15 15-16 22-24 24-25
exact bonds :
12-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:O,S,N

G2:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 12:CLASS
14:CLASS 15:CLASS 16:Atom 17:CLASS 22:CLASS 24:CLASS 25:Atom 31:CLASS
32:CLASS

```
Generic attributes :
9:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System     : Monocyclic

Element Count :
Node 9: Limited
    C,C3
    N,N1
    S,S1
    O,O0



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:53:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    41945 TO ITERATE

  4.8% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       826672 TO   851128
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 12:53:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   842311 TO ITERATE

100.0% PROCESSED   842311 ITERATIONS                               108 ANSWERS
SEARCH TIME: 00.00.12

L3          108 SEA SSS FUL L1

=> => s l3
L4          10 L3

=> d l4 1-10 bib,ab,hitstr
```

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1329661 CAPLUS
DN 144:69843
TI Preparation of pyrimidine derivatives and analogues as modulators of metabolism for the prophylaxis and treatment of metabolic-related disorders
IN Jones, Robert M.; Semple, Graeme; Xiong, Yifeng; Shin, Young-Jun; Ren, Albert S.; Lehmann, Juerg; Fioravanti, Beatriz; Bruce, Marc A.; Choi, Jin Sun Karoline
PA Arena Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 213 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005121121	A2	20051222	WO 2005-US19318	20050602
WO 2005121121	A3	20060316		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-577354P P 20040604

AB Title compds. I [where A1, A2 = (un)substituted alkylene; D = (un)substituted CH2 or NH; a is a single bond when E is N or (un)substituted CH, or a double bond when E is C; K = absence, cycloalkene or (un)substituted alkylene; Q1 = (un)substituted NH, O, S, SO or SO2; Q2 = (un)substituted NH or O; W = N or CH; X, Y, Z = N or (un)substituted CH; V = absence, (un)substituted (hetero)alkylene; Ar = (un)substituted (hetero)aryl, with one exclusion, and pharmaceutically acceptable salts, solvates, hydrates or N-oxides thereof] were prepared as modulators of metabolism For example, monosubstitution of 4,6-dichloropyrimidine with 4-[(methylamino)methyl]piperidine-1-carboxylic acid tert-Bu ester followed by Pd-catalyzed amination of the resultant chloride with 2-fluoro-4-methylsulfonylaniline both under microwave irradiation gave II. Several biol. assays were carried out. III is a RUP3 agonist and lowered blood glucose in a dose-dependent manner in mice with 14.83%, 22.03% and 39.31% inhibition of glucose excursion at the dose of 1, 3 and 10 mg/kg, resp. An analog of III stimulated RUP3 receptors with EC50 = 48 nM. Accordingly, compds. of the invention are useful in the treatment of metabolic-related disorders and complications thereof, such as diabetes and obesity.

IT **871680-77-2P**, 4-[[6-[[4-(3,4-Difluorophenyl)thiazol-2-yl]amino]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidine derivs. and analogs as modulators of metabolism for the prophylaxis and treatment of metabolic-related

disorders)

RN 871680-77-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[6-[[4-(3,4-difluorophenyl)-2-thiazolyl]amino]-4-pyrimidinyl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1068074 CAPLUS
DN 142:168974
TI Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays
AU Lombardo, Louis J.; Lee, Francis Y.; Chen, Ping; Norris, Derek; Barrish, Joel C.; Behnia, Kamelia; Castaneda, Stephen; Cornelius, Lyndon A. M.; Das, Jagabandhu; Doweyko, Arthur M.; Fairchild, Craig; Hunt, John T.; Inigo, Ivan; Johnston, Kathy; Kamath, Amrita; Kan, David; Klei, Herbert; Marathe, Punit; Pang, Suhong; Peterson, Russell; Pitt, Sidney; Schieven, Gary L.; Schmidt, Robert J.; Tokarski, John; Wen, Mei-Li; Wityak, John; Borzilleri, Robert M.
CS Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SO Journal of Medicinal Chemistry (2004), 47(27), 6658-6661
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:168974
AB A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematol. and solid tumor cell lines. Compound I was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, I was selected for addnl. characterization for oncol. indications.
IT **302962-38-5 302962-39-6 302962-56-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Discovery of a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclin. Assays)
RN 302962-38-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 302962-39-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 302962-56-7 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:967781 CAPLUS
DN 142:113953
TI Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56Lck inhibitors
AU Chen, Ping; Norris, Derek; Das, Jagabandhu; Spergel, Steven H.; Wityak, John; Leith, Leslie; Zhao, Rulin; Chen, Bang-Chi; Pitt, Sidney; Pang, Suhong; Shen, Ding Ren; Zhang, Rosemary; De Fex, Henry F.; Doweyko, Arthur M.; McIntyre, Kim W.; Shuster, David J.; Behnia, Kamelia; Schieven, Gary L.; Barrish, Joel C.
CS Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(24), 6061-6066
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 142:113953
AB A series of substituted 2-(aminoheteroaryl)-thiazole-5-carboxamide analogs have been synthesized as novel, potent inhibitors of the Src-family kinase p56Lck. Among them, compound I displayed superior in vitro potency and excellent in vivo efficacy.
IT **302962-56-7P 302962-61-4P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, Src-family kinase p56 inhibiting activity and structure-activity relationship of aminoheteroarylthiazolecarboxamides)
RN 302962-56-7 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-61-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:878168 CAPLUS
DN 141:360665
TI Synergistic methods and compositions using insulin-like growth factor 1 receptor (IGF1R) inhibitors with additional kinase inhibitors for treating cancer
IN Carboni, Joan M.; Hurlburt, Warren W.; Gottardis, Marco M.; Lee, Francis Y.
PA USA
SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 676,214.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209930	A1	20041021	US 2004-814199	20040331
	CA 2500714	AA	20040415	CA 2003-2500714	20031001
	US 2004072760	A1	20040415	US 2003-677067	20031001
	US 2004106605	A1	20040603	US 2003-676214	20031001
	EP 1551411	A2	20050713	EP 2003-759640	20031001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503867	T2	20060202	JP 2004-541997	20031001
	WO 2005094376	A2	20051013	WO 2005-US10820	20050330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-415416P	P	20021002		
	US 2003-676214	A2	20031001		
	US 2003-677067	A2	20031001		
	WO 2003-US31091	W	20031001		
	US 2004-814199	A	20040331		

OS MARPAT 141:360665
AB Combination therapies using IGF1R inhibitors in combination with addnl. kinase inhibitors are described for the synergistic treatment of cancer.
IT **302962-38-5 302962-39-6 302962-41-0**
302962-44-3 302962-45-4 302962-53-4
302962-54-5 302962-55-6 302962-56-7
302962-58-9 302962-60-3 302962-61-4
302962-62-5 302962-63-6 302962-65-8
302963-18-4 302963-20-8 302963-22-0
302963-24-2 302963-25-3 302963-26-4
302963-34-4 776295-45-5 776295-48-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IGF1 receptor inhibitors with addnl. kinase inhibitors for synergistic treatment of cancer)
RN 302962-38-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(4-

morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-39-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-41-0 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-44-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[(2R)-1-ethyl-2-pyrrolidinyl]methyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-45-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-53-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-54-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[(5-methylpyrazinyl)methyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-55-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(1H-1,2,3-triazol-1-yl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-56-7 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-58-9 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-60-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-61-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-62-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[(1-ethyl-2-pyrrolidinyl)methyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-63-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[(4-piperidinylmethyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-65-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1H-1,2,3-triazol-1-yl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-18-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(4-morpholinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-20-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(4-morpholinyl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-22-0 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-24-2 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-25-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(2-pyridinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-26-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(3-pyridinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-34-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-4-methyl-2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 776295-45-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 776295-48-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(1H-imidazol-4-yl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:412750 CAPLUS
DN 140:423687
TI Preparation of thiazolylamino-substituted pyrimidines as kinase inhibitors
IN Hartman, George D.; Hoffman, Jacob M.; Smith, Anthony M.; Tucker, Thomas J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041164	A2	20040521	WO 2003-US34100	20031024
	WO 2004041164	A3	20041007		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503715	AA	20040521	CA 2003-2503715	20031024
	EP 1558609	A2	20050803	EP 2003-779322	20031024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006507302	T2	20060302	JP 2004-550143	20031024
PRAI	US 2002-422313P	P	20021030		
	WO 2003-US34100	W	20031024		

OS MARPAT 140:423687
AB Title compds. I [X = O, S, amino; m,n = 0-3; R1-2, R4 = H, OH, alkoxy, CN, etc.; R3 = H, sulfonyl, acyl, carboxy, etc.; R5 = heterocyclyl] are prepared For instance, tert-Bu 4-[(6-aminopyrimidin-4-yl)oxy]piperidine-1-carboxylate (preparation given) is reacted with 2-chlorothiazole-5-carbonitrile (THF, NaH) and the resulting product deprotected (CH2Cl2, TFA) to give II. I inhibit, regulate and/or modulate kinase signal transduction; they are useful in the treatment of kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, retinal ischemia, macular edema, diabetic retinopathy and inflammatory diseases.
IT **691400-75-6P**, tert-Butyl 4-[[6-[(5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl]oxy]piperidine-1-carboxylate **691400-79-0P**, tert-Butyl 4-[[6-[(5-phenyl-1,3-thiazol-2-yl)amino]pyrimidin-4-yl]oxy]piperidine-1-carboxylate **691400-82-5P** **691400-85-8P**, tert-Butyl 4-[[[6-[(5-phenyl-1,3-thiazol-2-yl)amino]pyrimidin-4-yl]oxy]methyl]piperidine-1-carboxylate **691400-91-6P**, 2-[[2-Methyl-6-(piperidin-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691400-99-4P**, 2-[[2-Methyl-6-(piperidin-4-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-00-0P** **691401-17-9P**, tert-Butyl [4-[[[6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxy]methyl]piperidin-1-yl]acetate **691401-18-0P**, [4-[[[6-[(5-Cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-

yl]oxy]methyl]piperidin-1-yl]acetic acid **691401-45-3P**,
tert-Butyl 4-[[6-[(5-cyanothiazol-2-yl)amino]-2-methylpyrimidin-4-yl]amino]piperidine-1-carboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thiazolylamino-substituted pyrimidines as kinase inhibitors)

RN 691400-75-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[(5-cyano-2-thiazolyl)amino]-4-pyrimidinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691400-79-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[(5-phenyl-2-thiazolyl)amino]-4-pyrimidinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691400-82-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[6-[(5-cyano-2-thiazolyl)amino]-4-pyrimidinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691400-85-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[6-[(5-phenyl-2-thiazolyl)amino]-4-pyrimidinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-91-6 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(4-piperidinyloxy)-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-90-5
CMF C14 H16 N6 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-99-4 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(4-piperidinylmethoxy)-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-98-3
CMF C15 H18 N6 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-00-0 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-17-9 CAPLUS
CN 1-Piperidineacetic acid, 4-[[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-18-0 CAPLUS

CN 1-Piperidineacetic acid, 4-[[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691401-45-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT **691400-77-8P**, 2-[[6-(Piperidin-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691400-78-9P**, 2-[[6-(Piperidin-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691400-80-3P**, N-(5-Phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-yloxy)pyrimidin-4-amine **691400-81-4P**, N-(5-Phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-yloxy)pyrimidin-4-amine trifluoroacetate **691400-83-6P**, 2-[[6-(Piperidin-4-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691400-84-7P**, 2-[[6-(Piperidin-4-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691400-86-9P**, N-(5-Phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-ylmethoxy)pyrimidin-4-amine **691400-87-0P**, N-(5-Phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-ylmethoxy)pyrimidin-4-amine trifluoroacetate **691400-90-5P**, 2-[[2-Methyl-6-(piperidin-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691400-92-7P**, N-(5-Phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-yloxy)-2-methylpyrimidin-4-amine **691400-93-8P 691400-94-9P**, 2-[[2-Methyl-6-((3R)-pyrrolidin-3-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691400-95-0P**, 2-[[2-Methyl-6-((3R)-pyrrolidin-3-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691400-96-1P**, 2-[[2-Methyl-6-((3S)-pyrrolidin-3-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691400-97-2P**, 2-[[2-Methyl-6-((3S)-pyrrolidin-3-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691400-98-3P**, 2-[[2-Methyl-6-(piperidin-4-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-01-1P**, 2-[[2-Methyl-6-(morpholin-2-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-02-2P**, 2-[[2-Methyl-6-(morpholin-2-ylmethoxy)pyrimidin-4-

yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-03-3P**, 2-[[2-Methyl-6-(tetrahydro-2-pyran-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-04-4P**, 2-[[2-Methyl-6-(tetrahydro-2-pyran-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-05-5P**, 2-[[2-Isopropyl-6-(piperidin-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-06-6P**, 2-[[2-Isopropyl-6-(piperidin-4-yloxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-11-3P**, 2-[[2-Methyl-6-[[1-(2-(morpholin-4-yl)ethyl)piperidin-4-yl]oxy]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-15-7P**, 2-[4-[[6-[(5-Cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxy]piperidin-1-yl]-N-isopropylacetamide **691401-16-8P 691401-19-1P**, N-(tert-Butyl)-2-[4-[[[6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxy]methyl]piperidin-1-yl]acetamide **691401-20-4P**, 2-[[2-Methyl-6-(3-(morpholin-4-yl)propoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-21-5P**, 2-[[2-Methyl-6-(3-(morpholin-4-yl)propoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-22-6P**, 2-[[2-Methyl-6-(2-(morpholin-4-yl)ethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-23-7P**, 2-[[2-Methyl-6-(2-(morpholin-4-yl)ethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-24-8P**, 2-[[2-Methyl-6-(2-(piperidin-1-yl)ethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-25-9P 691401-26-0P**, 2-[[2-Methyl-6-[(2-(morpholin-4-yl)ethyl)amino]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-27-1P**, 2-[[2-Methyl-6-[(2-(morpholin-4-yl)ethyl)amino]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-29-3P**, 2-[[6-[(3-(Morpholin-4-yl)propyl)amino]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-30-6P**, 2-[[6-[(3-(Morpholin-4-yl)propyl)amino]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-31-7P**, 2-[[2-Methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-32-8P**, 2-[[6-[[3-(1H-Imidazol-1-yl)propyl]amino]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-33-9P 691401-34-0P 691401-35-1P**, 2-[[6-[(1,4-Dioxan-2-ylmethyl)amino]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-36-2P**, 2-[[6-[((1,4-Dioxan-2-yl)methyl)amino]-2-methylpyrimidin-4-yl]amino]thiazole-5-carbonitrile trifluoroacetate **691401-37-3P 691401-38-4P 691401-40-8P**, 2-[[2-Methyl-6-(tetrahydrofuran-3-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-41-9P**, 2-[[2-Methyl-6-(tetrahydrofuran-3-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-44-2P**, 2-[4-[[6-[(5-Cyanothiazol-2-yl)amino]-2-methylpyrimidin-4-yl]amino]piperidin-1-yl]-N-isopropylacetamide trifluoroacetate **691401-46-4P**, 2-[[2-Methyl-6-(piperidin-4-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-47-5P**, 2-[[2-Methyl-6-(piperidin-4-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-49-7P**, 2-[[2-Methyl-6-[(piperidin-4-ylmethyl)amino]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-50-0P**, 2-[[2-Methyl-6-[(piperidin-4-ylmethyl)amino]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate **691401-55-5P**, 2-[[2-Methyl-6-[(2-(morpholin-4-yl)ethyl)thio]pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-59-9P**, 2-[[6-(Piperidin-4-ylthio)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile **691401-60-2P**, 2-[[6-(Piperidin-4-ylthio)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile trifluoroacetate

691401-61-3P, 2-[4-[[6-((5-Cyanothiazol-2-yl)amino)-2-methylpyrimidin-4-yl]amino]piperidin-1-yl]-N-isopropylacetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolylamino-substituted pyrimidines as kinase inhibitors)

RN 691400-77-8 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-(4-piperidinyloxy)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691400-78-9 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-(4-piperidinyloxy)-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-77-8
CMF C13 H14 N6 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-80-3 CAPLUS
CN 4-Pyrimidinamine, N-(5-phenyl-2-thiazolyl)-6-(4-piperidinyloxy)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-81-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-phenyl-2-thiazolyl)-6-(4-piperidinyloxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-80-3
CMF C18 H19 N5 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-83-6 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-(4-piperidinylmethoxy)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-84-7 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-(4-piperidinylmethoxy)-4-pyrimidinyl]amino]-

, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-83-6
CMF C14 H16 N6 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-86-9 CAPLUS
CN 4-Pyrimidinamine, N-(5-phenyl-2-thiazolyl)-6-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-87-0 CAPLUS
CN 4-Pyrimidinamine, N-(5-phenyl-2-thiazolyl)-6-(4-piperidinylmethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-86-9
CMF C19 H21 N5 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-90-5 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(4-piperidinyloxy)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-92-7 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-N-(5-phenyl-2-thiazolyl)-6-(4-piperidinyloxy)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-93-8 CAPLUS
CN 4-Pyrimidinamine, 2-methyl-N-(5-phenyl-2-thiazolyl)-6-(4-piperidinyloxy)-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-92-7
CMF C19 H21 N5 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-94-9 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(3R)-3-pyrrolidinyloxy]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-95-0 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(3R)-3-pyrrolidinyloxy]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-94-9
CMF C13 H14 N6 O S

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-96-1 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(3S)-3-pyrrolidinyloxy]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691400-97-2 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(3S)-3-pyrrolidinyloxy]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691400-96-1
CMF C13 H14 N6 O S

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691400-98-3 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(4-piperidinylmethoxy)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-01-1 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(2-morpholinylmethoxy)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-02-2 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(2-morpholinylmethoxy)-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-01-1
CMF C14 H16 N6 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-03-3 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(2H-pyran-4-yloxy)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-04-4 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(2H-pyran-4-yloxy)-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-03-3
CMF C14 H11 N5 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-05-5 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-(1-methylethyl)-6-(4-piperidinyloxy)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-06-6 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-(1-methylethyl)-6-(4-piperidinyloxy)-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-05-5
CMF C16 H20 N6 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-11-3 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]oxy]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-15-7 CAPLUS
CN 1-Piperidineacetamide, 4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691401-16-8 CAPLUS
CN 1-Piperidineacetamide, 4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]-N-(1-methylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-15-7
CMF C19 H25 N7 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-19-1 CAPLUS
CN 1-Piperidineacetamide, 4-[[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]methyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-20-4 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[3-(4-morpholinyl)propoxy]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691401-21-5 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[3-(4-morpholinyl)propoxy]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-20-4

CMF C16 H20 N6 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691401-22-6 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[2-(4-morpholinyl)ethoxy]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691401-23-7 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[2-(4-morpholinyl)ethoxy]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-22-6

CMF C15 H18 N6 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691401-24-8 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[2-(1-piperidinyl)ethoxy]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-25-9 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[2-(1-piperidinyl)ethoxy]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-24-8
CMF C16 H20 N6 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-26-0 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691401-27-1 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-26-0

CMF C15 H19 N7 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691401-29-3 CAPLUS

CN 5-Thiazolecarbonitrile, 2-[[6-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-30-6 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-29-3
CMF C15 H19 N7 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-31-7 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-32-8 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-[[3-(1H-imidazol-1-yl)propyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-33-9 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[[(tetrahydro-1,1-dioxido-3-thienyl)methyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-34-0 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[[(tetrahydro-1,1-dioxido-3-thienyl)methyl]amino]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-33-9
CMF C14 H16 N6 O2 S2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-35-1 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-[(1,4-dioxan-2-ylmethyl)amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-36-2 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-[(1,4-dioxan-2-ylmethyl)amino]-2-methyl-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-35-1
CMF C14 H16 N6 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-37-3 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(tetrahydro-1,1-dioxido-3-thienyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-38-4 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(tetrahydro-1,1-dioxido-3-thienyl)amino]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-37-3
CMF C13 H14 N6 O2 S2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-40-8 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(tetrahydro-3-furanyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 691401-41-9 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(tetrahydro-3-furanyl)amino]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-40-8
CMF C13 H14 N6 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-44-2 CAPLUS
CN Acetamide, N-[2-[4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]amino]-1-piperidinyl]-1-methylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-43-1
CMF C19 H26 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-46-4 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(4-piperidinylamino)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-47-5 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-(4-piperidinylamino)-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-46-4
CMF C14 H17 N7 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-49-7 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(4-piperidinylmethyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-50-0 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[(4-piperidinylmethyl)amino]-4-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-49-7
CMF C15 H19 N7 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-55-5 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]thio]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-59-9 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-(4-piperidinylthio)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-60-2 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-(4-piperidinylthio)-4-pyrimidinyl]amino]-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-59-9
CMF C13 H14 N6 S2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-61-3 CAPLUS
CN 1-Piperidineacetamide, 4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]amino]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT **691400-89-2P**, tert-Butyl 4-[[6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxy]piperidine-1-carboxylate **691401-12-4P**, tert-Butyl [4-[[6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxy]piperidin-1-yl]acetate **691401-14-6P**, [4-[[6-[(5-Cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxy]piperidin-1-yl]acetic acid trifluoroacetate **691401-51-1P 691401-57-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolylamino-substituted pyrimidines as kinase inhibitors)
RN 691400-89-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-

pyrimidinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-12-4 CAPLUS
CN 1-Piperidineacetic acid, 4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-14-6 CAPLUS
CN 1-Piperidineacetic acid, 4-[[6-[(5-cyano-2-thiazolyl)amino]-2-methyl-4-pyrimidinyl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691401-13-5
CMF C16 H18 N6 O3 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691401-51-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[(5-cyano-2-thiazolyl)amino]-5-methyl-4-pyrimidinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 691401-57-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[(5-cyano-2-thiazolyl)amino]-4-pyrimidinyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:220082 CAPLUS
DN 140:253556
TI Preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors
IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John; Lombardo, Louis J.; Lee, Francis Y. F.
PA USA
SO U.S. Pat. Appl. Publ., 184 pp., Cont.-in-part of U.S. 6,596,746.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004054186	A1	20040318	US 2003-395503	20030324
	US 6596746	B1	20030722	US 2000-548929	20000413
	US 2004024208	A1	20040205	US 2003-378372	20030303
	US 6979694	B2	20051227		
	US 2004073026	A1	20040415	US 2003-378461	20030303
	US 2004077875	A1	20040422	US 2003-378373	20030303
	AU 2004223828	A1	20041007	AU 2004-223828	20040323
	CA 2519898	AA	20041007	CA 2004-2519898	20040323
	WO 2004085388	A2	20041007	WO 2004-US8827	20040323
	WO 2004085388	A3	20050630		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1610780	A2	20060104	EP 2004-758053	20040323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	US 2005261305	A1	20051124	US 2005-138793	20050525
	US 2005288303	A1	20051229	US 2005-138942	20050526
	NO 2005004359	A	20051019	NO 2005-4359	20050920
PRAI	US 1999-129510P	P	19990415		
	US 2000-548929	A2	20000413		
	US 2003-378373	A1	20030303		
	US 2003-395503	A	20030324		
	WO 2004-US8827	W	20040323		

OS MARPAT 140:253556
AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical composition comprising the title compds. is claimed.
IT **302962-38-5P 302962-39-6P 302962-41-0P**

302962-42-1P 302962-44-3P 302962-45-4P
302962-53-4P 302962-54-5P 302962-55-6P
302962-56-7P 302962-58-9P 302962-60-3P
302962-61-4P 302962-62-5P 302962-63-6P
302962-65-8P 302963-18-4P 302963-20-8P
302963-22-0P 302963-23-1P 302963-24-2P
302963-25-3P 302963-26-4P 302963-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302962-38-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 302962-39-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 302962-41-0 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-42-1 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1H-imidazol-2-yl)ethyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-44-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[(2R)-1-ethyl-2-pyrrolidinyl]methyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-45-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-53-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-54-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[(5-methylpyrazinyl)methyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-55-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(1H-1,2,3-triazol-1-yl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-56-7 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-58-9 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-60-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-61-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-62-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[(1-ethyl-2-pyrrolidinyl)methyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-63-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[(4-piperidinylmethyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-65-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1H-1,2,3-triazol-1-yl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-18-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(4-morpholinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-20-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(4-morpholinyl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-22-0 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-23-1 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(1H-imidazol-2-yl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-24-2 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-25-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(2-pyridinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-26-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(3-pyridinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 302963-34-4 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-4-methyl-2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:487561 CAPLUS
DN 137:63240
TI Preparation of thiazolyl inhibitors of Tec family tyrosine kinases
IN Barrish, Joel C.; Das, Jagabandhu; Kanner, Steven B.; Liu, Chunjian; Spergel, Steven H.; Witayk, John; Doweyko, Arthur M. P.; Furch, Joseph A.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050071	A1	20020627	WO 2001-US49430	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2433018	AA	20020627	CA 2001-2433018	20011219
	AU 2002031139	A5	20020701	AU 2002-31139	20011219
	EP 1347971	A1	20031001	EP 2001-991416	20011219
	EP 1347971	B1	20060301		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005506950	T2	20050310	JP 2002-551567	20011219
	US 2003069238	A1	20030410	US 2001-27982	20011220
	US 6706717	B2	20040316		
	US 2004067989	A1	20040408	US 2003-641876	20030815
	US 6956045	B2	20051018		
	US 2004067990	A1	20040408	US 2003-641933	20030815
	US 6958336	B2	20051025		
	US 2004077695	A1	20040422	US 2003-641535	20030815
	US 2004110752	A1	20040610	US 2003-642040	20030815
	US 6953795	B2	20051011		
	US 2006030598	A1	20060209	US 2005-236375	20050927
PRAI	US 2000-257830P	P	20001221		
	WO 2001-US49430	W	20011219		
	US 2001-27982	A3	20011220		
	US 2003-641535	A1	20030815		

OS MARPAT 137:63240
AB The title compds. [I; Q1 = thiazolyl; Q2 = (un)substituted (hetero)aryl; Z = O, S, NR4, etc.; R1 = H, OH, SH, etc.; R2, R3 = H, (un)substituted (hetero)aryl, (hetero)arylcarbonyl, etc.; R4 = H, alkyl, aryl, etc.], useful in the treatment of Tec family tyrosine kinase-associated disorders such as cancer, immunol. disorders and allergic disorders, were prepared E.g., a multi-step synthesis of the thiazole II, was given.
IT **439576-64-4P 439578-10-6P 439578-11-7P**
439578-14-0P 439578-27-5P 439578-32-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolyl inhibitors of Tec family tyrosine kinases)

RN 439576-64-4 CAPLUS
CN Piperazine, 1-acetyl-4-[2-methoxy-4-methyl-5-[[2-[[2-methyl-6-[methyl(1-methyl-2-pyrrolidinyl)amino]-4-pyrimidinyl]amino]-5-thiazolyl]thio]benzoyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439578-10-6 CAPLUS
CN Piperazine, 1-acetyl-4-[5-[[2-[[6-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-methyl-4-pyrimidinyl]amino]-5-thiazolyl]thio]-2-methoxy-4-methylbenzoyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439578-11-7 CAPLUS
CN Piperazine, 1-acetyl-4-[2-methoxy-4-methyl-5-[[2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]-5-thiazolyl]thio]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439578-14-0 CAPLUS
CN Piperazine, 1-acetyl-4-[2-methoxy-4-methyl-5-[[2-[[2-methyl-6-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]-5-thiazolyl]thio]benzoyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439578-27-5 CAPLUS
CN Piperazine, 1-[2-methoxy-4-methyl-5-[[2-[[2-methyl-6-[(1-methyl-4-piperidinyl)oxy]-4-pyrimidinyl]amino]-5-thiazolyl]thio]benzoyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 439578-32-2 CAPLUS

CN Piperazine, 1-acetyl-4-[2-methoxy-4-methyl-5-[[2-[[2-methyl-6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-pyrimidinyl]amino]-5-thiazolyl]thio]benzoyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:449449 CAPLUS
DN 137:33318
TI Preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors.
IN Bilodeau, Mark T.; Hartman, George D.; Hoffman, Jacob M., Jr.; Lumma, William C., Jr.; Manley, Peter J.; Rodman, Leonard; Sisko, John T.; Smith, Anthony M.; Tucker, Thomas J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English

Common Inv.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002045652	A2	20020613	WO 2001-US44573	20011130
	WO 2002045652	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002137755	A1	20020926	US 2001-990473	20011121
	CA 2429728	AA	20020613	CA 2001-2429728	20011130
	AU 2002032441	A5	20020618	AU 2002-32441	20011130
	EP 1341540	A2	20030910	EP 2001-991965	20011130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004524282	T2	20040812	JP 2002-547438	20011130
	US 2004063720	A1	20040401	US 2003-677687	20031002
PRAI	US 2000-251006P	P	20001204		
	US 2001-990473	A1	20011121		
	WO 2001-US44573	W	20011130		

ODP.

OS MARPAT 137:33318
AB Title compds. [I; A, B = N, NO; Y = O, S, NR4; R1, R2 = H, perfluoroalkoxy, OH, cyano, halo, (substituted) alkyl(oxy)(carbonyl), aryl(oxy)(carbonyl), heterocyclyl, etc.; R4 = H, aryl, alkyl; R5 = H, SO2Rc, CORc, Rc, CO2Rc; R6 = aryl, cyano, halo, (substituted) alkyl, alkenyl, alkynyl, heterocyclyl, aminocarbonyl; Rc = alkyl, aryl, heterocyclyl], were prepared for treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammation, etc. Thus, 4-aminopyrimidine was stirred with NaH in THF; 2-bromo-5-phenylthiazole was added and the mixture was refluxed overnight to give 5-phenylthiazol-2-yl pyrimidin-4-yl amine. I inhibited vascular endothelial growth factor-stimulated mitogenesis of human vascular endothelial cells with IC50 = 0.01-5.0 nM.
IT **436850-96-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors)
RN 436850-96-3 CAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-[methyl(4-piperidinylmethyl)amino]-4-pyrimidinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436850-95-2
CMF C15 H19 N7 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:526076 CAPLUS
DN 135:107338
TI Preparation of pyrimidine derivatives having antitumor effect
IN Tanaka, Hidekazu; Ueda, Kazuo; Suzuki, Shinji; Takenaka, Hideyuki
PA Shionogi and Co., Ltd., Japan
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051488	A1	20010719	WO 2001-JP36	20010109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2396324	AA	20010719	CA 2001-2396324	20010109
	AU 2001025466	A5	20010724	AU 2001-25466	20010109
	EP 1251129	A1	20021023	EP 2001-900628	20010109
	EP 1251129	B1	20040609		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 268769	E	20040615	AT 2001-900628	20010109
	ES 2222331	T3	20050201	ES 2001-1900628	20010109
	US 2003203894	A1	20031030	US 2002-169993	20020712
	US 6800630	B2	20041005		
PRAI	JP 2000-5553	A	20000114		
	WO 2001-JP36	W	20010109		

OS MARPAT 135:107338
AB Pyrimidine derivs. represented by the general formula (I), pharmaceutically acceptable salts thereof, or hydrates of the same [wherein R1, R2, R3 and R4 independently represent each hydrogen, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, nonarom. heteroaryl, or NH2, acyl, alkyloxy, HO, cyano, or NO2; or R1 and R2, R3 and R4, or R2 and R3 together with the N atom attached to them form a 3-7-membered ring optionally containing O, N, or S; R5 and R6 independently represent each hydrogen, (un)substituted alkyl, alkenyl, alkynyl, alkyloxycarbonyl, aryl, heteroaryl, or amino, alkylthio, halo, HO, SH, CO2H, cyano, NO2; RB and RC independently represent each hydrogen, alkyl, or alkyloxy, etc.; X represents O, S, NHNH, NH, or alkyl-N; Y represents (un)substituted (nonarom.) 5-membered heteroaryldiyl; and Z represents optionally substituted aryl or heteroaryl] are prepared These compds. have effects of inhibiting the ras cancer gene product downstream signal and inhibiting cell proliferation and, therefore, are useful as drugs such as antitumor agents, in particular for solid tumors in pancrea and large intestine and pulmonary adenocarcinoma. Thus, treatment of 4-amino-5-ethoxymethyl-2-methylpyrimidine in potassium tert-butoxide in DMF at room temperature for 1 h followed by addition reaction with Me isocyanate at room temperature for 2 h and then methylation with Me iodide at room temperature for 1

h gave N-(2-methyl-5-ethoxymethylpyrimidin-4-yl)-N-propyl-S-methylisothiourea. Condensation of the latter compound with dimethylhydrazine in ethanol at 65° for 3 days gave 1,1-dimethyl-2-(2-methyl-5-ethoxymethylpyrimidin-4-yl)-3-propylsemicarbazide which was treated with 25% HBr/AcOH at 70° for 7 h and condensed with 2-(4-nitrophenyl)-5-mercapto-1,3,4-oxadiazol in the presence of K2CO3 in DMF under ice-cooling for 1 h to give 2-[5-(1,3,4-oxadiazol-4-yl)pyrimidin-4-yl]semicarbazide derivative (II). II showed IC50 of 51.4, 0.4, 0.4, 0.4, 0.4, and 27.5 μg/mL against pulmonary adenocarcinoma A549, large intestine cancer HT-29, squamous pulmonary carcinoma Ma44, pancreatic cancer PANC-1, squamous pulmonary carcinoma RERF-LC-AI, and non-small cell lung H460 cells, resp.

IT **349606-90-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as inhibitors of ras cancer gene product downstream signal and antitumor agents)

RN 349606-90-2 CAPLUS

CN 4-Pyrimidinamine, N-(4,5-dihydro-2-thiazolyl)-2-methyl-5-[[[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]thio]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:756524 CAPLUS
DN 133:321878
TI Preparation of cyclic protein tyrosine kinase inhibitors
IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000062778	A1	20001026	WO 2000-US9753	20000412
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2366932	AA	20001026	CA 2000-2366932	20000412
	AU 2000042338	A5	20001102	AU 2000-42338	20000412
	AU 779089	B2	20050106		
	EP 1169038	A1	20020109	EP 2000-922102	20000412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009721	A	20020213	BR 2000-9721	20000412
	TR 200102969	T2	20020821	TR 2001-200102969	20000412
	JP 2002542193	T2	20021210	JP 2000-611914	20000412
	NZ 513639	A	20040227	NZ 2000-513639	20000412
	RU 2260592	C2	20050920	RU 2001-130452	20000412
	ZA 2001007204	A	20021202	ZA 2001-7204	20010830
	NO 2001004970	A	20011210	NO 2001-4970	20011012
	US 2005261305	A1	20051124	US 2005-138793	20050525
	US 2005288303	A1	20051229	US 2005-138942	20050526
PRAI	US 1999-129510P	P	19990415		
	WO 2000-US9753	W	20000412		
	US 2000-548929	A1	20000413		
	US 2003-378373	A1	20030303		

OS MARPAT 133:321878
AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day.
IT **302962-38-5P 302962-39-6P 302962-41-0P**
302962-42-1P 302962-44-3P 302962-45-4P
302962-53-4P 302962-54-5P 302962-55-6P
302962-56-7P 302962-58-9P 302962-60-3P
302962-61-4P 302962-62-5P 302962-63-6P
302962-65-8P 302963-18-4P 302963-20-8P
302963-22-0P 302963-23-1P 302963-24-2P
302963-25-3P 302963-26-4P 302963-34-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic protein tyrosine kinase inhibitors)

RN 302962-38-5 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 302962-39-6 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 302962-41-0 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-42-1 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1H-imidazol-2-yl)ethyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-44-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[(2R)-1-ethyl-2-pyrrolidinyl]methyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-45-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]amino]-2-methyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-53-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-54-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[(5-methylpyrazinyl)methyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-55-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(1H-1,2,3-triazol-1-yl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-56-7 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-58-9 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-60-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-61-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-62-5 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[(1-ethyl-2-pyrrolidinyl)methyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-63-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[(4-piperidinylmethyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302962-65-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[2-(1H-1,2,3-triazol-1-yl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-18-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(4-morpholinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-20-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(4-morpholinyl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-22-0 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-23-1 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(1H-imidazol-2-yl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-24-2 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-25-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(2-pyridinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-26-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[[[2-(3-pyridinyl)ethyl]amino]methyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 302963-34-4 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-4-methyl-2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 12:52:45 ON 08 APR 2006)

     FILE 'REGISTRY' ENTERED AT 12:52:53 ON 08 APR 2006
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS SAM
L3          108 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 12:53:56 ON 08 APR 2006
L4           10 S L3

     FILE 'CAOLD' ENTERED AT 12:54:33 ON 08 APR 2006

=> s l3
L5            0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44     219.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -7.50

STN INTERNATIONAL LOGOFF AT 12:54:44 ON 08 APR 2006
```